Furthermore, inhibition of Eg5 demonstrated efficacy in EGFR-TKI-resistant and cisplatin-resistant lung cancer cells, and combining Eg5 and BCL2L1 inhibitors effectively killed EGFR-mutant LUAD cells refractory to EGFR TKIs. This evidence concerns the gene BCL2L1 and lung carcinoma.